SCHEMBL2860111

SCHEMBL2860111

Brc1c2ccccc2c(-c2cccc3c2ccc2c(Br)c4ccccc4cc23)c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.45
ALDH1A1 P00352 4/20 0.39
HIF1A Q16665 3/20 0.39
HSD17B10 Q99714 3/20 0.39
HPGD P15428 3/20 0.39
MAPK1 P28482 2/20 0.39
TSHR P16473 1/20 0.39
CASP1 P29466 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CES1 P23141 1/20 0.38
CYP1B1 Q16678 1/20 0.38
POLB P06746 1/20 0.36
HPRT1 P00492 3/20 0.35
CYP1A2 P05177 3/20 0.35
ERBB2 P04626 1/20 0.35
FYN P06241 1/20 0.35
MAOA P21397 1/20 0.35
ACHE P22303 1/20 0.35
AHR P35869 1/20 0.35
MEN1 O00255 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13249096 0.97 SOS1 (0.47) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL13249094 0.97 SOS1 (0.47) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL13249095 0.92 SOS1 (0.43) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL2868561 0.92 SOS1 (0.43) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL13249086 0.91 ALDH1A1 (0.42) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL10052546 0.90 ALDH1A1 (0.44) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL13249090 0.89 SOS1 (0.45) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL18806368 0.88 SOS1 (0.41) SOS1ALDH1A1HIF1AHSD17B10TSHR
SCHEMBL13985502 0.88 SOS1 (0.41) SOS1ALDH1A1HIF1AHSD17B10HPGD
SCHEMBL17197649 0.86 ENPP1 (0.39) SOS1ALDH1A1HSD17B10HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8986852-B2 Benzanthracene derivatives for organic electroluminescent devices MERCK PATENT GMBH (DE) 2015-03-24 US disclosed
EP-2148909-B1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2012-05-30 EP disclosed
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES IDEMITSU KOSAN CO., LTD. (JP) 2010-07-29 US disclosed
EP-2148909-A2 NOVEL MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES Merck Patent GmbH (DE) 2010-02-03 EP disclosed
WO-2008145239-A2 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES MERCK PATENT GMBH (DE) 2008-12-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100187505-A1 BENZANTHRACENE DERIVATIVES FOR ORGANIC ELECTROLUMINESCENT DEVICES KCNT1, KCNC1, TMEM109 SOS1 3965/4885ALDH1A1 26/4885HIF1A 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.